Patents Assigned to Targanta Therapeutics, Inc.
  • Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections
    Patent number: 8404664
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 26, 2013
    Assignee: Targanta Therapeutics, Inc.
    Inventors: Yannick Stephane Rose, Stephane Ciblat, Ting Kang, Adel Rafai Far, Evelyne Dietrich, Yanick Lafontaine, Ranga Reddy
  • PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
    Publication number: 20100113333
    Abstract: The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 6, 2010
    Applicant: TARGANTA THERAPEUTICS, INC.
    Inventors: Kelly Tanaka, Adel Rafai Far, Stephane Ciblat, Evelyne Dietrich
  • Fragments and variants of DNAG primase, and uses thereof
    Patent number: 7326541
    Abstract: The invention relates to bacterial genes and proteins that are implicated in the process of DNA replication and also to bacteriophage genes and their protein products that interact with bacterial proteins involved in DNA replication. More particularly, the invention relates to compositions and methods involving an essential Staphylococcus aureus gene and its encoded protein STAAU_R9. In addition, the invention relates to screening assays to identify compounds which modulate the level and/or activity of STAAU_R9 and to such compounds.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: February 5, 2008
    Assignee: Targanta Therapeutics, Inc.
    Inventors: Jerry Pelletier, Philippe Gros, Michael DuBow, Dominique Bergeron
  • DNA sequences from bacteriophage 77 that encode anti-microbial polypeptides
    Patent number: 6982153
    Abstract: The disclosure concerns particular bacteriophage open reading frame, and portions and products of those open reading frames which have antimicrobial activity. Methods of using such products are also described.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: January 3, 2006
    Assignee: Targanta Therapeutics, Inc.
    Inventors: Jerry Pelletier, Philippe Gros, Michael DuBow